Forte Biosciences Ownership

FBRX Stock  USD 10.18  0.22  2.21%   
The market capitalization of Forte Biosciences is $124.34 Million. The majority of Forte Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Forte Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Forte Biosciences. Please pay attention to any change in the institutional holdings of Forte Biosciences as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2017-03-31
Previous Quarter
6.4 M
Current Value
11.4 M
Avarage Shares Outstanding
2.1 M
Quarterly Volatility
6.5 M
 
Covid
Some institutional investors establish a significant position in stocks such as Forte Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Forte Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Forte Stock Ownership Analysis

About 80.0% of the company shares are owned by institutional investors. The book value of Forte Biosciences was currently reported as 5.84. The company recorded a loss per share of 9.51. Forte Biosciences last dividend was issued on the 16th of June 2020. The entity had 1:25 split on the 28th of August 2024. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. Forte Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Forte Biosciences call Paul Wagner at 310 618 6994 or check out https://www.fortebiorx.com.
Besides selling stocks to institutional investors, Forte Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Forte Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Forte Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Forte Biosciences Quarterly Liabilities And Stockholders Equity

47.46 Million

Forte Biosciences Insider Trades History

About 9.0% of Forte Biosciences are currently held by insiders. Unlike Forte Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Forte Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Forte Biosciences' insider trades
 
Covid

Forte Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Forte Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Forte Biosciences backward and forwards among themselves. Forte Biosciences' institutional investor refers to the entity that pools money to purchase Forte Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2025-03-31
60.1 K
Longwood Capital Partners Llc2025-03-31
18.5 K
Millennium Management Llc2025-03-31
14.6 K
Blackrock Inc2025-03-31
6.8 K
Quest Partners Llc2025-03-31
4.2 K
Garde Capital, Inc.2025-03-31
K
Royal Bank Of Canada2025-03-31
3.3 K
Tower Research Capital Llc2025-03-31
1.8 K
Ubs Group Ag2025-03-31
527
Hhg Plc2025-03-31
920 K
Fred Alger Management, Llc2025-03-31
910.6 K
Note, although Forte Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Forte Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Forte Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Gryska David W over a month ago
Acquisition by Gryska David W of 148514 shares of Forte Biosciences at 1.01 subject to Rule 16b-3
 
Riley Antony A over a month ago
Acquisition by Riley Antony A of 375 shares of Forte Biosciences subject to Rule 16b-3
 
Paul Wagner over three months ago
Acquisition by Paul Wagner of 10520 shares of Forte Biosciences at 0.6988 subject to Rule 16b-3
 
Doberstein Stephen K over three months ago
Acquisition by Doberstein Stephen K of 31000 shares of Forte Biosciences at 7.54 subject to Rule 16b-3
 
Finck Barbara K over three months ago
Acquisition by Finck Barbara K of 31000 shares of Forte Biosciences at 7.02 subject to Rule 16b-3
 
Paul Wagner over three months ago
Acquisition by Paul Wagner of 31250 shares of Forte Biosciences subject to Rule 16b-3
 
Chen Hubert C over three months ago
Acquisition by Chen Hubert C of 7500 shares of Forte Biosciences subject to Rule 16b-3
 
Chen Hubert C over three months ago
Disposition of 2593 shares by Chen Hubert C of Forte Biosciences at 1.01 subject to Rule 16b-3
 
Riley Antony A over six months ago
Disposition of 375 shares by Riley Antony A of Forte Biosciences subject to Rule 16b-3
 
Paul Wagner over six months ago
Disposition of 1250 shares by Paul Wagner of Forte Biosciences subject to Rule 16b-3
 
Paul Wagner over six months ago
Disposition of 11046 shares by Paul Wagner of Forte Biosciences at 1.01 subject to Rule 16b-3
 
Riley Antony A over six months ago
Acquisition by Riley Antony A of 22514 shares of Forte Biosciences at 5.552 subject to Rule 16b-3

Forte Biosciences Outstanding Bonds

Forte Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Forte Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Forte bonds can be classified according to their maturity, which is the date when Forte Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Forte Biosciences Corporate Filings

8th of July 2025
Other Reports
ViewVerify
F4
3rd of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
25th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
24th of June 2025
Other Reports
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.